300 Participants Needed

Registry for Pulmonary Hypertension

(PHBR Trial)

Recruiting at 1 trial location
LR
LR
KC
LR
KC
Overseen ByKimberly Cygan, MBA, BSN, RN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Kansas Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to create a registry and biorepository to better understand pulmonary hypertension, a condition where high blood pressure affects the lungs and heart. By collecting and studying patient information and samples, researchers hope to improve future treatments. Ideal participants are adults diagnosed with pulmonary hypertension through a specific test called right heart catheterization.

As an unphased trial, this study allows participants to contribute to groundbreaking research that could lead to better treatments for pulmonary hypertension.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

Why are researchers excited about this trial?

Researchers are excited about the Pulmonary Hypertension Biorepository and Registry because it's not a treatment but a groundbreaking approach to understanding pulmonary hypertension better. Unlike current treatments that focus on managing symptoms, this registry and biorepository aims to collect extensive patient data and biological samples. This comprehensive collection can reveal new insights into the disease's progression and help identify potential targets for future therapies. By building a rich database, researchers hope to pave the way for more personalized and effective treatments down the line.

Who Is on the Research Team?

LR

Luigi R Boccardi, Ed.D., MPH

Principal Investigator

Director of Pulmonary Research

LA

Leslie A Spikes, MD

Principal Investigator

Assistant Professor of Medicine

Are You a Good Fit for This Trial?

Inclusion Criteria

The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
The participant has a diagnosis of pulmonary hypertension confirmed by right heart catheterization

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Collect clinically obtained data from current and deceased patients with pulmonary hypertension to support research

6 months

Biospecimen Collection

Establish a collection of biospecimens from patients with pulmonary hypertension and correlate them to longitudinally collected individual patient data

12 months

Collaboration

Provide biospecimens to researchers investigating pulmonary hypertension

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Registry and Biorepository

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Kansas Medical Center

Lead Sponsor

Trials
527
Recruited
181,000+